THIS ANNOUNCEMENT DOES
NOT CONSTITUTE A PROSPECTUS OR PROSPECTUS EQUIVALENT DOCUMENT AND
NEITHER THIS ANNOUNCEMENT NOR ANYTHING HEREIN FORMS THE BASIS FOR
ANY OFFER TO PURCHASE OR SUBSCRIBE FOR ANY SHARES OR OTHER
SECURITIES IN THE COMPANY NOR SHALL IT FORM THE BASIS FOR ANY
CONTRACT OR COMMITMENT WHATSOEVER.
6 November
2024
Oxford Nanopore
Technologies plc
Approval of the
transfer of listing category
Further to the
announcement on 8 October 2024, Oxford Nanopore Technologies
plc is pleased to announce
the approval by the Financial Conduct Authority (the
"FCA") of the
transfer of listing category of its ordinary shares from
the equity shares
(transition) category to the equity shares (commercial companies)
category on the official list of the FCA, in accordance with Rule
21.5 of the UK Listing Rules as modified by
Transitional Provision 2 (the
"Transfer").
The Transfer will take
effect at 8:00 a.m. GMT today.
For further
information, please contact:
Oxford Nanopore
Technologies plc
Investors: ir@nanoporetech.com
Media: media@nanoporetech.com
Citigroup Global Markets
Limited (Joint Corporate
Broker and Sponsor)
Robert Way
Richard
Abel
Patrick
Evans
+44 (0)20 7500
5000
Teneo
(communications adviser to the Company)
Tom Murray
Olivia
Peters
+44 (0) 20 7353
4200
OxfordNanoporeTechnologies@teneo.com
About Oxford
Nanopore Technologies plc:
Oxford Nanopore
Technologies' goal is to bring the widest benefits to society
through enabling the analysis of anything, by anyone, anywhere. The
Group has developed a new generation of nanopore-based sensing
technology that is currently used for real-time, high-performance,
accessible, and scalable analysis of DNA and RNA. The technology is
used in more than 125 countries, to understand the biology of
humans, plants, animals, bacteria, viruses and environments as well
as to understand diseases such as cancer. Oxford Nanopore's
technology also has the potential to provide broad, high impact,
rapid insights in a number of areas including healthcare, food and
agriculture.
For more information
please visit: www.nanoporetech.com
Forward-looking
statements
This announcement
contains certain forward-looking statements. For example,
statements regarding expected revenue growth and profit margins are
forward-looking statements. Phrases such as "aim", "plan",
"expect", "intend", "anticipate", "believe", "estimate", "target",
and similar expressions of a future or forward-looking nature
should also be considered forward-looking statements.
Forward-looking statements address our expected future business and
financial performance and financial condition, and by definition
address matters that are, to different degrees, uncertain. Our
results could be affected by macroeconomic conditions, the COVID-19
pandemic, delays in our receipt of components or our delivery of
products to our customers, suspensions of large projects and/or
acceleration of large products or accelerated adoption of pathogen
surveillance. These or other uncertainties may cause our actual
future results to be materially different than those expressed in
our forward-looking statements.